Improving Hypertension Control in Safety-Net Settings: The Boston Hypertension Equity Alliance in Treatment

NCT ID: NCT06948838

Last Updated: 2025-10-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

16895 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-08

Study Completion Date

2029-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

High blood pressure (BP) or hypertension (HTN) affects over 100 million individuals in the US, increasing the risk of adverse outcomes, including stroke, myocardial infarction (MI), and chronic kidney disease (CKD). Effective therapies include non-pharmacologic approaches and multiple medication classes. Successful HTN management requires ongoing patient engagement for BP monitoring and treatment intensification. Reaching this goal is challenging, and many patients with HTN do not have controlled BP.

Using a collaborative partnership between patients, clinicians, health system and public health stakeholders, and the research team the investigators plan to overcome barriers to widespread implementation of evidence-based health system strategies to improve BP control in a large, urban, primary care-based safety-net setting for diverse populations experiencing disparities in HTN-related outcomes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A hybrid type 1 effectiveness-implementation study will be implemented to evaluate the comparative impact of each intervention on clinical outcomes while also assessing implementation at each site. The multi-site cluster randomized stepped-wedge design allows for feasible resource allocation and sequential roll out of the interventions for comparison, ensuring each site has the opportunity to benefit from both approaches. Data will be collected for multiple patient reported outcomes (PROs) to understand the range of impacts of the interventions from the patient perspective.

The specific aims are to:

* Assess comparative effectiveness of remote BP monitoring (RBPM) versus RBPM + multilevel intensification intervention (MII) on HTN control and quality of care. Prior research has demonstrated the effectiveness of each of these interventions yet the optimal approach to achieve equity in HTN control in safety net practices remains unknown.
* Use mixed methods, guided by the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework, to assess implementation of the two comparators as measured by reach, adoption, implementation (fidelity) and maintenance. Using a convergent parallel design, the investigators will use concurrent quantitative and qualitative data to obtain perspectives across multiple levels to understand the reasons for success or failure of implementation of each comparator. By merging these data, integration can be achieved by using qualitative themes related to implementation to support or refute quantitative findings of reach and fidelity.
* Evaluate the comparative impacts of each intervention on PROs assessed with validated measures of patient activation, medication adherence, and trust in medical settings. The study intervention approaches were informed by direct feedback from the targeted diverse patients and clinical providers to address patient-reported barriers to HTN control: lack of activation, adherence to medications, and trust in their care providers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension Hypertension Complicated

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

A hybrid type 1 effectiveness-implementation study with a cluster randomized stepped wedge study design will be used. This will be a longitudinal repeated measures design. RBPM will begin for all clusters in September, 2025. At the end of month 12, MII implementation will begin for the group in the first wedge, with the second and third groups implementing at 6-month intervals thereafter. All sites will continue interventions as part of ongoing operations, with final long-term follow-up assessment at the end of month 54.
Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Remote Blood Pressure Monitoring (RBPM)

Individual level interventions fo monitor blood pressure.

Group Type EXPERIMENTAL

RBPM

Intervention Type BEHAVIORAL

Standardized blood pressure measurement and treatment protocols in clinical practice.

Multilevel Intensification interventions (MII)

Team-based interventions to mitigate clinical inertia which is the lack of intensification of treatment despite inadequate disease control such as for HTN.

Group Type EXPERIMENTAL

RBPM

Intervention Type BEHAVIORAL

Standardized blood pressure measurement and treatment protocols in clinical practice.

MII

Intervention Type OTHER

Team-based interventions including multiple evidence-proven interventions such as clinician decision support, monitoring medication non-adherence, use of combination pills, and formulary modifications.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RBPM

Standardized blood pressure measurement and treatment protocols in clinical practice.

Intervention Type BEHAVIORAL

MII

Team-based interventions including multiple evidence-proven interventions such as clinician decision support, monitoring medication non-adherence, use of combination pills, and formulary modifications.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult (age\>18) patients receiving primary care at one of the 9 participating sites, with primary care provider (PCP) visit in the preceding year
* Presence of HTN defined by one or more of: 1) diagnosis included on active problem list, 2) active HTN medications in prior year, 3) 3 separate elevated BP measurements
* Uncontrolled HTN defined as systolic blood pressure (SBP)\>140
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Patient-Centered Outcomes Research Institute

OTHER

Sponsor Role collaborator

Boston Healthcare for the Homeless Program (BHCHP)

UNKNOWN

Sponsor Role collaborator

Boston Medical Center General Internal Medicine primary care (BMC GIM)

UNKNOWN

Sponsor Role collaborator

Boston Medical Center Family Medicine Primary Care (BMC FM)

UNKNOWN

Sponsor Role collaborator

NeighborHealth Center Family Medicine at Maverick Street (NH FM)

UNKNOWN

Sponsor Role collaborator

NeighborHealth Center Internal Medicine at Gove Street (NH IM)

UNKNOWN

Sponsor Role collaborator

NeighborHealth South End (NH South End)

UNKNOWN

Sponsor Role collaborator

Manet Community Health Center (Maner CHC)

UNKNOWN

Sponsor Role collaborator

Mattapan Community Health Center (Mattapan)

UNKNOWN

Sponsor Role collaborator

Greater Roslindale Medical and Dental Center (GRMDC)

UNKNOWN

Sponsor Role collaborator

Boston University School of Public Health (BUSPH)

UNKNOWN

Sponsor Role collaborator

BUSPH Biostatistics and Epidemiology Data Analytics Center (BEDAC)

UNKNOWN

Sponsor Role collaborator

Boston Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michael Fischer, MD MS

Role: PRINCIPAL_INVESTIGATOR

Boston Medical Center, Internal Medicine

Cheryl Clark, MD ScD

Role: PRINCIPAL_INVESTIGATOR

Institute for Health Equity Research, Evaluation & Policy, MA League of CHCs

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Boston Healthcare for the Homeless (BHCHP)

Boston, Massachusetts, United States

Site Status RECRUITING

Boston Medical Center Family Medicine

Boston, Massachusetts, United States

Site Status RECRUITING

Boston Medical Center, General Internal Medicine primary care

Boston, Massachusetts, United States

Site Status RECRUITING

Neighborhood Health

Boston, Massachusetts, United States

Site Status RECRUITING

Mattapan Community Health Center

Boston, Massachusetts, United States

Site Status RECRUITING

Manet Community Health Center

Quincy, Massachusetts, United States

Site Status RECRUITING

Greater Roslindale Medical and Dental Center (GRMDC)

Roslindale, Massachusetts, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Michael Fischer, MD MS

Role: CONTACT

(617) 414-7288

Justine Scott, MPH

Role: CONTACT

(617) 414-7288

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HMC-2023C2-33345

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

H-45398

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.